0001209191-22-023285.txt : 20220405 0001209191-22-023285.hdr.sgml : 20220405 20220405182350 ACCESSION NUMBER: 0001209191-22-023285 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220401 FILED AS OF DATE: 20220405 DATE AS OF CHANGE: 20220405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galimi Francesco CENTRAL INDEX KEY: 0001823996 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38359 FILM NUMBER: 22808674 MAIL ADDRESS: STREET 1: 12930 VIA ESPERIA CITY: DEL MAR STATE: CA ZIP: 92014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adicet Bio, Inc. CENTRAL INDEX KEY: 0001720580 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813305277 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET STREET 2: FLOOR 6 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-482-2333 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET STREET 2: FLOOR 6 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: resTORbio, Inc. DATE OF NAME CHANGE: 20171024 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-01 0 0001720580 Adicet Bio, Inc. ACET 0001823996 Galimi Francesco C/O ADICET BIO, INC. 200 CLARENDON STREET, FLOOR 6 BOSTON MA 02116 0 1 0 0 SVP & Chief Medical Officer Common Stock 2022-04-01 4 M 0 7621 5.97 A 67538 D Common Stock 2022-04-01 4 S 0 7621 21.00 D 59917 D Common Stock 2022-04-04 4 M 0 6036 13.27 A 65953 D Common Stock 2022-04-04 4 S 0 6036 21.00 D 59917 D Common Stock 2022-04-04 4 M 0 168 5.97 A 60085 D Common Stock 2022-04-04 4 S 0 168 21.00 D 59917 D Common Stock 2022-04-04 4 M 0 1775 16.82 A 61692 D Common Stock 2022-04-04 4 S 0 1775 21.00 D 59917 D Employee Stock Option (Right to Buy) 5.97 2022-04-01 4 M 0 7621 D 2029-10-15 Common Stock 7621 113820 D Employee Stock Option (Right to Buy) 13.27 2022-04-04 4 M 0 6036 0.00 D 2031-01-12 Common Stock 6036 73964 D Employee Stock Option (Right to Buy) 5.97 2022-04-04 4 M 0 168 D 2029-10-15 Common Stock 168 113652 D Employee Stock Option (Right to Buy) 16.82 2022-04-04 4 M 0 1775 0.00 D 2031-02-11 Common Stock 1775 26625 D This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021. A total of 128,424 shares subject to an employee stock option were received as described in footnote (3). 25% of the shares vested on September 23, 2020, and 1/36th of the remaining unvested shares vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting date. Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. A total of 28,400 shares subject to an employee stock option were granted on February 12, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. /s/ Nick Harvey, Attorney-in-Fact 2022-04-05